The PEC-01 cell population, differentiated from human embryonic stem cells (hESCs), contains pancreatic progenitors (PPs) that, when loaded into macroencapsulation devices (to produce the VC-01 candidate product) and transplanted into mice, can mature into glucose-responsive insulin-secreting cells and other pancreatic endocrine cells involved in glucose metabolism. We modified the protocol for making PEC-01 cells such that 73%-80% of the cell population consisted of PDX1-positive (PDX1 + ) and NKX6.1 + PPs. The PPs were further differentiated to islet-like cells (ICs) that reproducibly contained 73%-89% endocrine cells, of which approximately 40%-50% expressed insulin. A large fraction of these insulin-positive cells were single hormone-positive and expressed the transcription factors PDX1 and NKX6.1. To preclude a significant contribution of progenitors to the in vivo function of ICs, we used a simple enrichment process to remove remaining PPs, yielding aggregates that contained 93%-98% endocrine cells and 1%-3% progenitors. Enriched ICs, when encapsulated and implanted into mice, functioned similarly to the VC-01 candidate product, demonstrating conclusively that in vitro-produced hESC-derived insulin-producing cells can mature and function in vivo in devices. A scaled version of our suspension culture was used, and the endocrine aggregates could be cryopreserved and retain functionality. Although ICs expressed multiple important b cell genes, the cells contained relatively low levels of several maturity-associated markers. Correlating with this, the time to function of ICs was similar to PEC-01 cells, indicating that ICs required cell-autonomous maturation after delivery in vivo, which would occur concurrently with graft integration into the host. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:1-9 SIGNIFICANCE Type 1 diabetes (T1D) affects approximately 1.25 million people in the U.S. alone and is deadly if not managed with insulin injections. This paper describes the production of insulin-producing cells in vitro and a new protocol for producing the cells, representing another potential cell source for a diabetes cell therapy. These cells can be loaded into a protective device that is implanted under the skin. The device is designed to protect the cells from immune rejection by the implant recipient. The implant can engraft and respond to glucose by secreting insulin, thus potentially replacing the b cells lost in patients with T1D.
INTRODUCTION
In type I diabetes, autoimmunity results in the loss of insulin-producing b cells in the pancreas, leading to a loss of blood glucose control. The standard treatment of insulin injection is lifesaving; however, daily glucose fluctuations remain higher than in healthy persons. This leaves patients vulnerable to complications including vascular and kidney disease, blindness, and lower limb amputation. Transplantation of cadaveric islets has made great progress in recent years and can result in insulin independence or lower insulin requirements [1] . This approach, however, is greatly limited by donor availability and the need for chronic immunosuppression.
Human embryonic stem cells (hESCs) possess the key features of essentially unlimited expansion and the theoretical ability to differentiate to any cell type, thus there has been considerable effort toward developing protocols to produce b-like cells from hESCs for transplantation and drug development. Significant advances have been made over the past 10 years in recapitulating pancreatic development in vitro with hESCs, using the extensive knowledge gained from studies of pancreatic organogenesis in model organisms [2] . We have previously shown that pancreatic endoderm cells (PECs) differentiated from hESCs via a four-stage protocol can, when transplanted into immunodeficient mice, form functional b cells and reverse streptozotocin-induced diabetes [3, 4] ; this result has been reproduced by others [5] . We also demonstrated a scaled manufacturing system capable of producing the required quantity and quality of PEC-01 cells (PECs derived from CyT49 hESCs) to enable clinical application [6] .
To potentially circumvent the need for immune suppression when implanting allogeneic hESC-derived pancreatic cells into patients with type I diabetes, a particularly attractive approach is to encapsulate the cell product. We optimized a planar macroencapsulation device containing a semipermeable barrier (the Encaptra drug delivery system) that can be loaded with PEC-01 cells and implanted subcutaneously. The implanted cell/device combination product (the VC-01 candidate product; ViaCyte, Inc., San Diego, CA, http://viacyte.com) can mature and function in mice (unpublished data), as described for nonencapsulated grafts, and has the benefit of being easily retrievable. Others have recently published results using a similar device, the TheraCyte device (TheraCyte Inc., Laguna Hills, CA, http:// www.theracyte.com/TheTechnology.htm), with similar outcomes [7, 8] . We are currently testing VC-01 in a clinical trial (ClinicalTrials.gov identifier NCT02239354).
PECs generated from hESCs in vitro are mixed populations that contain multipotent pancreatic progenitors (PPs), pancreatic endocrine progenitors and precursors, and pancreatic endocrine cells. The endocrine cells in PECs often express multiple hormones and, in the case of cells expressing insulin, are deficient in expression of essential b cell markers (e.g., NKX6.1 and PDX1) and do not respond appropriately to glucose stimulation. These polyhormonal cells have been characterized in detail in recent studies [9] [10] [11] [12] . Our group has demonstrated previously that purified and reaggregated cultures of PECs that were highly enriched for PPs and depleted of endocrine cells can differentiate to endocrine lineages in vivo including functional b cells, but purified and reaggregated polyhormonal endocrine cells do not [3] . This proves that PPs generated in vitro are sufficient to generate b cells in vivo. Whether the polyhormonal insulin-expressing cells are immature cells or whether they are inappropriately differentiated and not analogous to cell types produced during normal pancreas development is not known definitively.
In this study, we described the development of a sevenstage differentiation protocol that produced highly enriched cultures of pancreatic endocrine cells in vitro (designated "ICs" [islet-like cells]). The first four stages of our IC protocol built on our PEC-01 protocol and increased the PP content into the range of 73%-80% while greatly reducing (polyhormonal) endocrine cell content. Stage 5 was designed to efficiently direct endocrine lineage commitment. Conditions supporting endocrine differentiation were optimized in stages 6 and 7, resulting in cultures consisting of 73%-89% endocrine cells and less than 10% PPs. Importantly, insulin-expressing cells produced by this method coexpressed other pancreatic hormones at a reduced frequency and coexpressed NKX6.1 and PDX1 at a higher frequency compared with the standard four-stage protocol. Methods producing endocrine cells from hESCs with these expression attributes have been described recently [13, 14] .
The stage 7 cells, when encapsulated and implanted into mice, were capable of producing b-like cells that functioned at a level similar to that of implanted PEC-01 cells; however, because a low but significant percentage of PPs was present in these cultures, we could not rule out that it was PPs, and not endocrine cells produced in vitro, that resulted in functional cells in vivo. We used a dissociation/reaggregation process through which cell aggregates were enriched for endocrine cells and depleted of PPs. When implanted within devices, enriched ICs released human C-peptide in response to glucose, proving that highly purified endocrine cells differentiated in vitro from hESCs can produce functional b-like cells. Importantly, the kinetics of functional maturation in vivo are similar to those of PEC-01 cells, indicating that IC insulinexpressing cells are immature prior to implant.
MATERIALS AND METHODS
All methods are described in the supplemental online data.
RESULTS
Data from 10 independent experiments (numbered 1-10) are described.
Protocol Optimization for Pancreatic Progenitor Content
In our four-stage suspension culture-based PEC-01 protocol, hESC differentiation progresses through the intermediate stages of definitive endoderm (stage 1), primitive gut tube (stage 2), and posterior foregut (PF; stage 3) and then to a stage 4 population consisting of, on average (49 experiments), 32% PPs and 52% chromogranin A-expressing endocrine cells, the majority of which are polyhormonal [6] . In developing the IC protocol, we initially aimed to increase the PPs and reduce the endocrine content of the cell population at the end of stage 4. In PEC-01 and many similar differentiation protocols, neurogenin 3 (NEUROG3, also known as NGN3)-a master regulator of endocrine development [15] -is induced during stage 3. This occurs at the same time as PDX1 induction but well before other critical PP markers, such as NKX6.1 and PTF1A (i.e., in PF cells, not PPs). It seemed plausible that induction of the endocrine program in PF cells by NGN3 expression could be an important contributor to the generation of polyhormonal endocrine cells. We hypothesized that suppressing NGN3 through stages 3 and 4 might lead to decreased endocrine and increased PP content at the end of stage 4 and that, with further differentiation steps, endocrine cells that were more properly specified could be produced from PPs.
We modified the PEC-01 protocol by additionally treating with activin A, Wnt3A, and heregulin b1 at stage 3 (days 5-7) and with activin A and heregulin b1 at stage 4 (days 7-13). The PEC-01 and IC (stages 1-4) protocols are shown in schematic form in supplemental online Table 2 ). Specifically, IC differentiations yielded, on average, approximately 2.5-fold more PPs (75% vs. 32%) and more than 3-fold lower endocrine (14% vs. 52%) cell content (supplemental online Table 2 ). An activin concentration of either 50 or 75 ng/ml at stage 3 was used in the experiments shown in supplemental online Table 2 . The higher concentration may have had a slightly increased effect (supplemental online Table 2) but also resulted in a lower cell yield (data not shown); therefore, activin at 50 ng/ml was used in all other experiments. The IC protocol was also compared with the PEC-01 protocol by digital RNA analysis. Stage 4 IC cultures had higher expression levels of PP genes (e.g., PDX1, NKX6.1, and SOX9) (Fig. 1A ) and lower levels of endocrine genes (e.g., CHGA, INS, GCG, SST) (Fig. 1B) than did PEC-01 cultures. Looking at NGN3 expression over time (Fig. 1C) , a marked reduction was observed during stage 3 in the IC protocol relative to PEC-01. Significant NGN3 expression occurred during stage 4 in ICs; however, it remained well below that in PEC-01 populations. Consequently, we achieved a cell population that was enriched in PP cells and that had much reduced (premature) endocrine commitment from which to optimize endocrine differentiation. Protocol stages 1-4 were essentially the same for all experiments except for a modestly higher stage 3 activin concentration in experiments 1 and 9, as noted.
Endocrine Lineage Commitment From PPs
The next step, stage 5 (days 13-15), was designed to maximize induction of NGN3. It is well documented that the Notch pathway is a negative regulator of NGN3 [16] . On ligand binding to Notch receptor, g-secretase cleaves the receptor, releasing the Notch intracellular domain, which is part of a complex, including HES (hairy and enhancer of split) proteins, that represses NGN3 transcription [17]; therefore, g-secretase inhibitors (GSIs) can inhibit Notch signaling activity and upregulate NGN3 expression. We tested the GSI designated RO4929097 [18] for its ability to promote endocrine differentiation from PPs. As seen in Figure 1D , NGN3 was strongly induced by this GSI, with a peak of expression at day 15 (of the days analyzed), followed by a reduction in expression by day 18 (i.e., 3 days after GSI withdrawal). Comparing NGN3 levels at day 15 in nontreated versus GSI-treated cells, a 17-fold enhancement was observed with treatment ( Fig. 1D) . Stage 5 treatments were the same in all experiments shown.
Optimization of Insulin Expression and Endocrine Maturation
During stages 6 and 7, we optimized for expression of insulin and mature b cell genes. A schematic of stages 5-7 is shown in supplemental online Table 3A . The resulting populations were analyzed by flow cytometry, digital gene expression, and immunofluorescence and for proinsulin and C-peptide content. Because testing was performed at intervals during the optimization process the data presented in this study had varying treatments at stages 6 and 7. This is detailed in the supplemental online data (Methods section) and in supplemental online Table 4 . During the iterative process, some factors that had been beneficial in early experiments had no positive effect in later versions of the protocol. Examples of such factors are BMP4 and TTNPB, which were not used in the current IC protocol (supplemental online Table 4 ). The thyroid hormone triiodothyronine was added based on studies suggesting involvement in b cell maturation [19] . Nicotinamide has been shown to potentiate differentiation of fetal islets in vitro [20] . The Rhoassociated kinases (ROCKs) have roles in multiple cellular functions such as adhesion, motility, proliferation, and apoptosis [21] , and the ROCK inhibitor (ROCKi) Y-27632 can increase survival of hESCs [22] .
As shown in supplemental online Fig. 2) showed the strong induction of early endocrine genes (e.g., NGN3, PAX4), followed by hormone genes (e.g., INS, GCG and SST) and mature b cell markers (e.g., GCK, PCSK1 and SLC30A8). We note that these maturity genes are not necessarily specific to b cells. Other mature b cell genes were expressed at very low levels relative to islets (e.g., IAPP and MAFA; data not shown). The expression patterns of PAX4 and ARX are interesting regarding possible dominance of GCG over INS expression in various paradigms [3, 9, 24].
Enrichment of Endocrine Cells via Dissociation and Reaggregation
A major goal of this work was to prove that endocrine cells produced in vitro were able to mature and function in vivo. To accomplish this, a highly enriched endocrine preparation would be required, to preclude any contribution from PPs present in heterogeneous populations. We built on a relatively simple enrichment technique described previously [3] . That study showed that PEC-01 aggregates could be enzymatically dissociated and then reaggregated in rotating suspension culture. The resulting aggregates were enriched in endocrine cells and depleted of PPs. In contrast, the inclusion of ROCKi in the aggregation medium allowed survival and incorporation of PP into the aggregates. We removed ROCKi from the IC differentiation medium on the last day of stage 6, then dissociated and reaggregated ICs on the first day of stage 7, when the hormone genes were nearing peak expression. The cells within the resulting endocrine-enriched clusters were very loosely adhered, as observed previously [3] . The following day, we added ROCK inhibitor and a source of extracellular matrix in the form of very dilute, and thus soluble, Matrigel (Corning Inc., Corning, NY, https://www. corning.com). The combination of these two components greatly increased the degree of cell-cell interaction within the clusters and, consequently, the stability of the aggregates (supplemental online Fig. 1) .
Reaggregated ICs were then differentiated through stage 7. Stages 5-7 for native (i.e., not reaggregated) ICs and reaggregated ICs are shown in schematic form in supplemental online Table 3 . In Experiments 2 and 3, as measured by flow cytometry, reaggregated ICs contained 98% and 93% endocrine cells and 1% and 3% PPs, respectively (supplemental online Table 6 ). Compared with native ICs, reaggregated ICs were modestly enriched in endocrine markers (e.g., CHGA, INS, and GCG) and highly depleted for SOX9, a PP marker that is not expressed in endocrine cells (Fig. 3) . The mature b cell genes PCSK1 and SLC30A8 were expressed in both native and reaggregated ICs at levels approaching (particularly in experiment 3) those found in isolated human islets (Fig. 3) . As noted, these maturity genes are not necessarily specific to b cells. 
Proinsulin Processing by ICs Compared With Human Islets
To further assess the maturity of stage 7 insulin-producing cells, we quantified the amount of C-peptide (which is generated by processing of proinsulin to insulin) present in the cells and the percentage of proinsulin that was fully processed compared with purified human islets (Fig. 5) . The mean values for C-peptide levels, in micrograms of C-peptide per microgram of DNA (i.e., normalized to cell content), were 0.31 for islets and 0.15 for ICs (Fig. 5A ). The mean percentages of proinsulin processed in islets and ICs were 96% and 90%, respectively (Fig. 5B ). We concluded that ICs produced very significant levels of insulin and C-peptide (albeit approximately twofold lower than islets) and processed proinsulin essentially as efficiently as human islets do.
In Vivo Assessment of IC Populations
We tested whether ICs could mature and exhibit glucosestimulated insulin secretion (GSIS) in the in vivo setting. Five cohorts of SCID/beige mice were implanted with ICs loaded into Encaptra macroencapsulation devices in 3 experiments (experiments 2-4). In experiment 2, native ICs were compared with reaggregated ICs; experiment 3 compared native ICs that had been cryopreserved with reaggregated ICs; and experiment 4 consisted of native ICs only. The results of GSIS assays in grafted mice from experiments 2 and 3, tested at 8, 12, and 16 weeks after transplant, are shown in Figure 6 . The serum C-peptide values plotted in Figure 6 , and additional values from experiment 4 are shown in supplemental online Table 7 . The IC-implanted mouse cohort data were compared with our database of mice similarly implanted with VC-01 in unrelated experiments. At 8 weeks, the median glucose-stimulated C-peptide values were comparable for all cohorts and ranged from 326 to 539 pmol/l with the VC-01 controls at 375 pmol/l. As described (supplemental online  Table 6 ), the reaggregated IC populations contained 98% (experiment 2) and 93% (experiment 3) CHGA + endocrine cells. Importantly, these data prove that in vitro differentiated insulin-producing cells can mature and function in vivo. These cohorts were not tested at time points earlier than 8 weeks because in pilot experiments with ICs, we did not see a robust GSIS response prior to this time (data not shown); however, these earlier experiments, which were not yet well optimized, also had relatively low GSIS values at later time points (data not shown). At 12 weeks after implant, the GSIS values increased considerably in all cohorts, with median values for the ICengrafted groups between 468 and 848 pm serum C-peptide at 60 minutes following glucose injection. There was no clear correlation between median C-peptide values and native, reaggregated, or cryopreserved cell implants. The median value for the PEC-01 grafts was considerably higher, at 1830 pmol/l C-peptide, compared with the IC grafts; however, the significance of this is unclear because of the relatively small number of animals implanted with ICs. Stimulated C-peptide values increased again at 16 weeks after implant, and the native IC and VC-01 groups had similar median glucose-stimulated C-peptide values. At this time point there was a trend toward the reaggregated IC cohorts having median values below those of the native IC groups and the PEC-01 controls. This would not be particularly surprising considering the harsh nature of the reaggregation process; however, as noted, the number of animals implanted was too few to be definitive. In summary, ICs, including populations that were essentially pure endocrine cells or that had been cryopreserved, were capable of maturing in a device in vivo and subsequently responding appropriately to glucose stimulation by releasing insulin. 
Histological Analysis of Explanted IC Grafts
IC grafts were removed between 18 and 24 weeks after implant. GSIS assay results in the week of or the week prior to explant are shown in supplemental online Tables 8-10 (experiments 2-4, respectively). Robust function was maintained through the latest time point examined (24 weeks) (supplemental online Table 9 ). Highfunctioning grafts were chosen for immunofluorescent staining ( Fig. 7 ; supplemental online Figs. 5, 6) (experiments 2, 3, and 4, respectively). Almost all INS + cells expressed both PDX1 and NKX6.1. Hormones were very rarely, if ever, coexpressed. As with IC aggregates in vitro, there were few SST + cells in the IC grafts. The immunofluorescent analyses of grafts from native, reaggregated, and cryopreserved native IC appeared substantially similar.
DISCUSSION
We developed an in vitro differentiation protocol that produces pancreatic endocrine cells from hESCs. This protocol built on our previous 4-stage protocol [6] by modifying stages 3 and 4 such that the NKX6.1 + /PDX1
+ PP pool was increased to 73%-80% (supplemental online Table 2 ). This was accomplished with the addition of activin A, Wnt3A, and heregulin b1. We previously found that activin A is capable of suppressing NGN3 and increasing PP content; however, at effective concentrations, activin A treatment resulted in a reduction of cell yield (data not shown). Wnt3A was capable of counteracting this cell loss, allowing the use of relatively high concentrations of activin A and, in fact, resulted in a net increase in cells at the end of stage 3 (data not shown). We have not addressed whether this effect of Wnt3A was due to increased proliferation, decreased cell death, decreased migration of cells from aggregates (and into the medium and subsequently aspirated on daily feeding), or a combination of these. Wnt signaling has been shown to promote proliferation of PPs in the developing mouse pancreas [25] , and activin family signaling has been implicated in pancreas specification [26] , although because of the complexity of these pathways, the particular ligands used in vivo are not well established. Others have used relatively low concentrations of activin A similarly in their hESC-to-pancreatic cell differentiation protocols [10] . Heregulin b1 also decreased the loss of cells, although not as potently as did Wnt3A. In addition, low concentrations of heregulin b1 were used because higher concentrations increased expression of CDX2, a posterior gut marker (data not shown). When differentiated through stage 7, IC populations could be macroencapsulated, implanted, and matured in vivo to glucoseresponsive b-like cells (Fig. 6) . The ability to form functional grafts while protected from cell-cell interactions with the immune system is a critical component of any potential allogeneic cell therapy for diabetes. Furthermore, as proof of the efficacy of in vitro-derived endocrine cells, we showed that enriched ICs, largely depleted of PPs, can function similarly to native ICs ( Fig. 6 ; supplemental online Table 6 ). Because ICs contain some polyhormonal cells, as seen in supplemental online Table 5 , it is possible that they can mature and contribute to in vivo function. The small fraction of PPs remaining in enriched ICs (supplemental online Table 6 ) likely contribute, at most, a small fraction of the in vivo activity. Another critical component of a potential cell therapy is the ability to cryopreserve and recover the cell product, and that ability was demonstrated in this study (Fig. 6) .
Two important reports that pancreatic endocrine cells produced from hESCs in vitro can also function in vivo were published recently [13, 14] . The in vivo studies in the reports were performed with nonencapsulated cells. Remarkably, the endocrine cells produced in vitro were shown to respond to glucose in vitro in both publications, with an approximately twofold stimulation index (which was similar to human islet controls). We do not see a reproducible response to glucose by insulin-producing cells generated with our IC protocol (data not shown). We have not directly compared the cells generated by the three protocols; nonetheless, some interesting observations can be made. All three protocols produce endocrine cells that are approximately 50% INS + , and a high proportion of these are We noted that the time at which endocrine induction was promoted by addition of a GSI was the same (day 13) among the 3 protocols. This may be related to the previously described [27] competence windows of pancreatic progenitors for the formation of the various endocrine cell types. Consequently, cells produced by all three regimens have very important similarities despite relatively divergent protocols. Concerning the time required to first observe in vivo function, we consistently saw a significant GSIS response at 8 weeks with both IC and PEC-01 protocols, not far from the 6 weeks reported by 
Methods

Ethics Statement
The CyT49 cell line (NIH Registration Number 0041) was ethically derived from a donated embryo with informed consent. Animal experiments were performed at Neurocrine Biosciences, Inc., San Diego, CA and were approved by their Institutional Animal Care and Use Committee, protocol # V-12-01.
Human Embryonic stem cell (hESC) culture. The CyT49 hESC line (NIH registration number 0041) was cultured as described [6] . Briefly, hESC were grown in monolayer culture in DMEM/F12 with Glutamax, plus 10% (v/v) xeno-free serum replacement, 1% (v/v) non-essential amino acids, 1% (v/v) penicillin/streptomycin (all from Life Technologies), 10 ng/mL Heregulin-1 (Peprotech), and 10 ng/mL Activin A (R&D Systems). Cultures were dissociated to single cells with Accutase (Innovative Cell Technologies) and re-plated every 3 to 4 days. 10% (v/v) solublephase human AB serum (Valley Biomedical) was added to the medium for cell attachment on the first day of each passage only. Cells were used for differentiation studies between passages 27 and 33 only.
hESC aggregation. Cells were placed in suspension culture in 6-well plates essentially as described [6] , or alternatively in 500 mL bottles for larger experiments. Briefly, hESC monolayers were dissociated with Accutase (Innovative Cell Technologies), collected and resuspended at 1x10 6 cells/mL in StemPro hESC SFM (Life Technologies; combined DMEM/F12 containing Glutamax, StemPro hESC supplement, BSA, and 1% (v/v) Penicillin/streptomycin; omitted FGF-2 and 2-Mercaptoethanol). The single cell suspensions were dispensed to non-TC treated 6-well plates (5.5 mL/well) and rotated at 95 rpm on an Innova 2000 rotator (New Brunswick Scientific), or dispensed to 500 mL Nalgene filter receiver storage bottles (150 mL/bottle) and rotated at 65 rpm on a Sartorius Certomat RM-50 rotator (configured with a 5 cm axis of rotation). Cells were rotated overnight in a 37 o C/8% CO 2 incubator and formed aggregates of approximately 100-200M. hESC aggregate differentiation. Differentiation to PEC-01 in 6-well plates was essentially as described in [6] ; alternatively, the protocol was scaled-up for use in 500mL bottles. Stages 1 and 2 of IC differentiation were identical to PEC-01.
Stage 1 (2 days; protocol days 0-2): hESC aggregates were collected, centrifuged at 500 rpm for 1 minute, and washed with stage 1/2 base medium (RPMI 1640 supplemented with 1% (v/v) Glutamax, 1% (v/v) penicillin/streptomycin (all from Life Technologies), and 0.2% (v/v) FBS (Hyclone)). Aggregate pellet volume was measured and used to determine the number of vessels required for differentiation. 6-well plates required 33 mL medium and 80 L cells, and bottles required 150 mL medium and 350 L cells. Cells were distributed in Stage 1/2 base medium supplemented with ITS-G (Life Technologies, 1:5000 dilution), Activin A (100ng/mL, R&D Systems), and Wnt3a (50ng/mL, R&D Systems). Plates were rotated at 95 rpm, and bottles at 70 rpm, in a 37 o C/8% CO 2 incubator. On day 1, cells were fed with the same medium minus Wnt3a. Medium was changed daily; feeding volumes were 4.5 mL for plates and 140 mL for bottles.
Stage 2 (3 days; protocol days 2-5): Day 2 used Stage 1/2 base medium with ITS-G (Life Technologies, 1:1000 dilution), TGF RI Kinase inhibitor IV (2.5 M, EMD Bioscience), and KGF (25 ng/mL, Peprotech). Days 3 and 4 used same medium minus TGFRI kinase inhibitor. Plates were rotated at 95 rpm on days 2 and 3 and at 105 rpm on day 4; and bottles were rotated at 70 rpm. Stage 4 (6 days; protocol days 7-13): For PEC-01, stage 3/4/5 base medium plus Noggin (50 ng/mL, R&D Systems), KGF (50 ng/mL, Peprotech), and EGF (50 ng/mL, Peprotech) was used. IC medium additionally contained Activin A (5 ng/mL, R&D Systems) and Heregulin-1 (5 ng/mL, Peprotech) on days 7-10 only. Plates were rotated at 105 rpm on day 7 and at 95 rpm on days 8-13; and bottles were rotated at 68 rpm.
Stage 5 (2 days; protocol days 13-15): Stages 5-7 are performed for IC only. Cells were treated with stage 3/4/5 base medium with Noggin (50 ng/mL, R&D Systems), KGF (50 ng/mL, Peprotech), EGF (50 ng/mL, Peprotech), -secretase inhibitor (GSI) RO4929097 (0.5 M, Cellagen Technology), and Rho-associated protein kinase inhibitor (ROCKi) Y-27632 (10 M, Tocris Bioscience). B-27 could be substituted with the combination (referred to as B-27 substitute) of ITS-G (0.5% (v/v), Life Technologies), chemically defined lipid concentrate (0.5% (v/v), Life Technologies), and BSA (0.2% (wt/v), Millipore). Aggregates were typically collected from bottles and redistributed to plates at this stage (can also be done at stages 6 or 7) to facilitate multi-variable testing. Plates were rotated at 100 rpm and bottles at 70 rpm. (25 nM, Sigma-Aldrich), TTNPB (1 nM, Sigma-Aldrich), BMP4 (10 ng/mL, Peprotech), Matrigel (0.05% (v/v), BD Biosciences), and IGF2 (50 ng/mL, R&D systems). Many iterative experiments have led to a current procedure which includes, of the above 'additional supplements', ROCKi and Nicotinamide at stage 6, and ROCKi, Nicotinamide, Matrigel, and T 3 at stage 7. The start day of stage 7 was not critical and occasionally occurred 1 day later or earlier than day 20. Plates were rotated at 100 rpm and bottles at 70 rpm.
Re-aggregation for endocrine cell enrichment: Re-aggregation was performed similarly as described [3] . All experiments that included a re-aggregation step utilized DMEM-containing stage 6/7 base medium at stage 6 and on the day of re-aggregation; re-aggregation in CMRLcontaining medium has not been optimized. Re-aggregation occurred on day 20, but could also be performed at least 1 day earlier or later. Cells were fed with medium without ROCKi on the day prior to, and the day of re-aggregation. Aggregates were washed twice in DPBS (without calcium and magnesium, Life Technologies) with centrifugation at 500 rpm for 1 minute. Drawing of aggregates into pipettes or tips is avoided from this step until after dissociation as aggregates become very sticky at this point. Cell pellet volume was measured and used to determine reagent volume for the next step. Aggregates were dissociated with Accumax (Innovative Cell Technologies) at room temperature; 4 mL enzyme solution and 2 mL DPBS (without calcium and magnesium) were used per 100 L pellet volume. Aggregates were triturated with a P1000 pipettor after 10 minutes of digestion, and every 2-3 minutes thereafter, until a single cell suspension is achieved. The reaction must be monitored closely to avoid excessive cell lysis. Three volumes of DMEM-containing stage 6/7 base medium were added and mixed with cells, and an aliquot was removed to obtain a cell count. Cells were centrifuged at 1000 rpm for 5 minutes. Cells were resuspended at 1x10 6 cells/mL in DMEMcontaining stage 6/7 base medium (which does not contain ROCKi) plus DNAse I (10 Units/μl, Roche). 5 mL cell suspension was added per well of each 6-well plate, and the plates were rotated at 95 rpm. The following day, cells were very gently collected (cells are loosely adherent), allowed to settle, washed with stage 6/7 base medium, resuspended, and distributed to plates in stage 7 medium. The composition of stage 7 medium is detailed in Supplementary Table 4 , and contained ROCKi and Matrigel for all re-aggregated conditions. . Flow cytometry data were acquired with a FACSCalibur (BD Biosciences), using excitation lines at 488 nm and 635 nm and detecting fluorescence at 530+/-15 nm, 585+/-21 nm, and 661+/-8 nm. Data were analyzed using FlowJo software (Tree Star, Inc.). Intact cells were identified based on forward (low angle) and side (orthogonal, 90u) light scatter. To account for the varying levels of autofluorescence observed in these complex samples, additional gating of intact cells (2-3 subpopulations) was performed, and cells were subsequently analyzed for fluorescence intensity. Background was estimated using unstained, secondary-antibody alone, or irrelevant antibody controls, as appropriate. In some figures, a representative flow cytometry plot is shown from one of the sub-populations. Numbers reported on plots and in tables represent the percentage of total cells from the intact cells gate.
Gene expression analysis:
Total RNA was isolated from duplicate biological samples using the ABI Prism 6100 Nucleic Acid Prep Station (Applied BioSystems) and associated ABI materials and reagents per manufacturer's instructions. Gene Expression was determined using 100ng per sample of total RNA in the NanoString Technologies nCounter analysis system per manufacturer's instructions utilizing custom code sets designed at ViaCyte, Inc. and produced by NanoString Technologies. Briefly, per sample reaction, sample RNA (100ng) was combined with reporter code set and capture probe set and allowed to hybridize overnight at 65°C. The next day, purification and binding reactions were performed in the nCounter PrepStation. Subsequently, the cartridge containing hybridized, purified target RNA bound to fluorescent barcode was placed into the nCounter Digital Analyzer for counting at 1155 FOV per sample. Once the samples were analyzed on the nCounter® Digital Analyzer, a Reporter Code Count (RCC) output file was generated containing the count data for the controls and probe/target complexes in the samples. The RCC file was imported into the Genedata Analyst™ software program (Genedata AG., Switzerland) using the NanoString parser developed by Genedata AG., for RCC files. The parser directly imports the RCC file, annotates all gene data by accession number including positive and negative controls, and performs a quality control analysis of the experiment. The quality control analysis results are reported in the Genedata Analyst™ program as "good" or "bad", which corresponds to passing or failing, respectively, of the nCounter assay quality control criteria. Within the program, the gene expression data was then normalized using a fixed target value for the geometric mean of the housekeeping genes (ACTB, PPIG, POLR2A, and TBP) multiplexed into the custom code set. The normalized gene expression values can then be directly compared between samples in the same experiment as well as samples in other experiments (that use the same codeset) since all data is normalized to the same fixed target value. Data in figure 1 was generated using codeset A while figures 2 and 3 utilized codeset B.
Content analysis of IC aggregates and human islets:
Three different lots of human islets were purchased from ProCell Biotech, LLC. IC aggregates and human islets were homogenized using the Bullet Blender®. To each sample tube, 200 L of RNase-free zirconium-oxide beads (Next Advance, Inc.) were added along with 300 L of cold TE buffer (20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA) supplemented with 1 L of SUPERase• In™ RNase Inhibitor (Life Technologies). The tubes were placed in the Bullet Blender® and run twice with the speed control set at 8 for 4 minutes. The tubes were placed in ice for at least 1 min between each run. Once homogenized, the lysates were divided into 2 fractions: #1) 40 L of lysate was diluted 1:2 in water in the presence of protease inhibitors, for protein content analysis; and #2) 15 L of the lysate was diluted 1:20 in UltraPure™ DNase/RNase-Free Distilled Water (Life Technologies) for measurement of DNA concentration. DNA was quantified using the PicoGreen® dsDNA Quantitation Kit (Life Technologies). C-peptide content was measured using the C-peptide ELISA kit, product number 10-1136-01 (Mercodia) and proinsulin was measured using the Proinsulin ELISA kit, product number 10-1118-01 (Mercodia). The ELISA's were performed according to the manufacturer's instruction manuals.
Immunofluorescent Staining: Differentiated hES cell-derived aggregates were fixed with 4% (wt/v) paraformaldehyde for 1 hour at room temperature, washed with PBS, and then equilibrated in 30% sucrose at 4°C overnight. Aggregates were mounted with Optimal Cutting Temperature Compound (Tissue-Tek) to make frozen blocks and were cut into 8 μm sections. Devices were fixed in 10% (v/v) neutral buffered formalin (Fisher Scientific) for 6-30 hours at room temperature then processed for paraffin embedding using the Leica ASP300S Advanced Smart Processor. Devices were cut into 5 µM sections which were deparaffinized and rehydrated in preparation for staining. For the Insulin/PDX1/NKX6.1 co-staining, both frozen (cell aggregates) and paraffin (grafts in devices) sections underwent heat-induced epitope retrieval prior to staining. Sections were washed with PBS twice for 10 minutes followed by PBST (PBS/0.2% (v/v) Tween20; Thermo Fisher Scientific) for 15 minutes. Blocking was done for 1 hour at room temperature with 5% (v/v) normal donkey serum (Jackson ImmunoResearch Labs)/PBSTr (PBS/0.1% (v/v) Triton X-100 (Sigma)). Primary and secondary antibodies were diluted in 1% (wt/v) BSA (Sigma)/ PBSTr. Primary antibodies were incubated at 4°C overnight and secondary antibodies for 1 hour 15 minutes in a moisture chamber at room temperature. The following primary antibodies and dilutions were used: guinea pig anti-insulin, 1:500 (Dako, A0564); rabbit anti-somatostatin, 1:300 (Dako, A0566); mouse anti-glucagon, 1:200 (Sigma, G2654); mouse anti-NKX6-1, 1:20 (Developmental Studies Hybridoma Bank, F55A12, used for staining of frozen sections); goat anti-NKX6-1, 1:500 (LSBio, LS-C124275, used for paraffin sections); and rabbit anti-PDX1, 1:500 (Epitomics, 3470-1). The following secondary antibodies were used at a dilution of 1:500: Cy3-conjugated donkey anti-goat, Cy5-conjugated donkey antiguinea pig (both from Jackson ImmunoResearch Laboratories), Alexa Fluor-488 donkey antirabbit, and Alexa Fluor-555 donkey anti-mouse (both from Life Technologies). Imaging was done by confocal microscopy (Olympus FV1000) and acquired with Olympus FluoView software. Digital processing of images was performed using Adobe Photoshop. Manipulations included cropping a portion of an image from a larger field and adjusting the levels of each color channel on the entire image.
Encapsulation and Transplantation: Encaptra-20 devices were wetted with base culture medium. IC were collected and gravity settled in 1.5 mL tubes and 10 L aliquots of cell pellet (approximately 3 x 10 6 cells) were pipetted to individual tubes containing approximately 0.5mL base medium. An aliquot of cells and medium was delivered through the device loading port with a catheter/syringe assembly. The device port was sealed with medical-grade silicone adhesive and trimmed. SCID beige mice were anesthetized with ketamine/xylazine and supplemental isoflurane. For implant, a lateral dorsal incision was made, and a subcutaneous pocket was created by blunt dissection with a hemostat. The loaded device was placed in the pocket, and the incision was closed with surgical clips. IC were implanted at day 29 (Experiment #2), day 27 (Experiment #3), or day 26 (Experiment #4) of in vitro differentiation.
Glucose Stimulated Insulin Secretion (GSIS) Assay: Graft function was assessed by performing measurement of serum human C-peptide in response to glucose administration essentially as described [6] . Prior to the GSIS assay, mice were fasted for approximately 15-18 hours. Glucose was administered via intraperitoneal injection of a 30% dextrose (Hospira) solution at a dose of 3.0 g/kg body weight, and blood was collected prior to (fasting) and at 30 and/or 60 minutes after glucose administration. Blood samples of approximately 50 L were collected by retroorbital sinus puncture under isoflurane anesthesia and transferred to microtainer tubes (BD Biosciences, cat#365956) containing blood/serum separation gel. Serum was collected after spinning these tubes at 4000-6000 x g for 10 minutes. Human C-peptide was measured using the Mercodia Ultrasensitive Human C-peptide ELISA, cat#10-1141-01. We regard the lower limit of accurate quantitation of human C-peptide in serum samples to be 50 pM [4] . The level of cross-detection of mouse C-peptide is <1%, or a maximum of 30 pM in glucose stimulated control mice. The level of cross-detection of human insulin is <0.0006% and of proinsulin is <1.8%. 
